Tracey L Mclaughlin

Title: Tracey L Mclaughlin: Innovator in Pharmaceutical Formulations

Introduction

Tracey L Mclaughlin is a notable inventor based in Santa Clara, CA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of innovative treatments for hyperinsulinemic hypoglycemia.

Latest Patents

Mclaughlin holds a patent for "Buffered formulations of exendin (9-39)." This patent describes liquid pharmaceutical formulations that comprise exendin (9-39) or a pharmaceutically acceptable salt thereof, along with a tonicity modifier in a physiologically acceptable buffer. The formulations are designed to have a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation includes exendin (9-39) in an acetate buffer or a citrate buffer. The patent also outlines methods for treating or preventing hyperinsulinemic hypoglycemia by administering the buffered liquid formulation to a subject. Mclaughlin has 1 patent to his name.

Career Highlights

Throughout his career, Mclaughlin has worked with prestigious organizations, including Leland Stanford Junior University and Amylyx Pharmaceuticals Inc. His work has focused on advancing pharmaceutical science and improving patient outcomes through innovative formulations.

Collaborations

Mclaughlin has collaborated with notable colleagues, including Xiaofeng Xiong and Colleen M Craig. These collaborations have contributed to the development of his patented formulations and further advancements in the field.

Conclusion

Tracey L Mclaughlin is a distinguished inventor whose work in pharmaceutical formulations has the potential to significantly impact the treatment of hyperinsulinemic hypoglycemia. His innovative approaches and collaborations highlight his commitment to advancing medical science.